- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about AMGN
Recent news which mentions AMGN
Top US Drugmakers Exploit US Patent System To Keep Generic Competition At Bay: Report
September 16, 2022
From Benzinga
Amgen’s new cancer drug faces questions about competition
September 15, 2022
From MarketWatch
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
September 14, 2022
From Benzinga
From Motley Fool
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report
September 13, 2022
From Benzinga
Livent, Amgen And Some Other Big Stocks Moving Lower On Monday
September 12, 2022
From Benzinga
From InvestorPlace
Here's Why Amgen Shares Are Diving
September 12, 2022
From Benzinga
From Benzinga
3 Stocks Expecting Good News From the FDA
September 12, 2022
From Motley Fool
Amgen's Lumakras Cuts Risk Of Progression By 34% In KRAS-Mutated Lung Cancer Patients
September 12, 2022
Tickers
AMGN
From Benzinga
Bristol Myers' Deucravacitinib Scores FDA Approval For Plaque Psoriasis
September 12, 2022
From Benzinga
Could This Biosimilar Drug Candidate Be a Winner for Amgen?
September 09, 2022
From Motley Fool
7 Dow Stocks With Superior Fundamentals
September 06, 2022
From InvestorPlace
Is This Blue Chip Dividend Stock a Buy?
September 05, 2022
From Motley Fool
These 3 S&P 500 Dividend Stocks Have High Compound Annual Growth Rates Through 2024
September 03, 2022
From Benzinga
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
September 01, 2022
Tickers
AMGN
From Benzinga
From Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 30, 2022
From Benzinga
20 dividend stocks with high yields that are expected to raise payouts the most through 2024
August 30, 2022
From MarketWatch
From Motley Fool
U.S.-China relations just got a whole lot better, boosting the prospects of these three stocks
August 28, 2022
From MarketWatch
These 10 stocks matter the most to hedge funds right now
August 24, 2022
From MarketWatch
2 Top Biotech Stocks to Buy for the Long Haul
August 24, 2022
From Motley Fool
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 23, 2022
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.